---
title: "Supercharging CAR T Cell Therapy: A Step Toward Longer-Lasting Cancer Remissions"
description: CAR T cell therapy limiter has been found, allows for higher resistance to cancer over time.
---

<https://immunaeon.com/blog>

# [Supercharging CAR T Cell Therapy: A Step Toward Longer-Lasting Cancer Remissions](https://immunaeon.com/blog/supercharging-car-t-cell-therapy-a-step-toward-longer-lasting-cancer-remissions)

 Written by [Genti Gashi](https://immunaeon.com/blog/author/genti-gashi) | Oct 13, 2025, 9:53:13 PM

CAR T cell therapy has redefined what’s possible in cancer treatment, achieving remarkable responses in patients with blood cancers. Yet, a central challenge remains: these engineered T cells can lose strength over time, leading to relapse in diseases like multiple myeloma.

A recent **Nature** study offers a compelling path forward. By applying *in vivo* CRISPR screening—an approach that tests dozens of genetic edits in parallel—researchers identified molecular “brakes” that limit CAR T cell durability. Among them, one gene stood out: **CDKN1B**, a regulator of the cell cycle that restrains T cell proliferation.

When CDKN1B was removed, CAR T cells demonstrated striking improvements. They expanded more robustly, maintained cytotoxic function under repeated stimulation, and persisted longer in preclinical myeloma models. Importantly, CAR T cells engineered from patient samples showed the same advantage, pointing to a strategy that is both scientifically rigorous and clinically relevant.

For the field, these results underscore the potential of integrating functional genomics into CAR T design. Targeted genetic modifications such as CDKN1B deletion could extend the therapeutic window of CAR T therapy—transforming it from a treatment that induces remission into one that sustains it.

The takeaway is clear: CAR T therapy is not only powerful today, it is poised to become even more durable and effective tomorrow. With discoveries like this, the vision of long-lasting, relapse-resistant cell therapies is moving closer to clinical reality.

 

Reference:

Knudsen, N.H., Escobar, G., Korell, F. *et al.* In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. *Nature* (2025). https://doi.org/10.1038/s41586-025-09489-8

[View full post](https://immunaeon.com/blog/supercharging-car-t-cell-therapy-a-step-toward-longer-lasting-cancer-remissions)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Genti Gashi"
  },
  "dateModified" : "2025-10-13T21:53:13.581Z",
  "datePublished" : "2025-10-13T21:53:13Z",
  "headline" : "Supercharging CAR T Cell Therapy: A Step Toward Longer-Lasting Cancer Remissions",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1024,
    "url" : "https://23263141.fs1.hubspotusercontent-na1.net/hubfs/23263141/AI-Generated%20Media/Images/generate%20a%20picture%20of%20an%20hour%20glass.png",
    "width" : 1024
  },
  "mainEntityOfPage" : "https://immunaeon.com/blog/supercharging-car-t-cell-therapy-a-step-toward-longer-lasting-cancer-remissions",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Immunaeon Blog"
  }
}
```